Fineline Cube

Follow:
14691 Articles
Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
CompanyDrug

Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients

Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand
Company

Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand

Company

Genentech Pledges USD 750 Million for Oregon Device Fill‑Finish Plant, Expanding Roche’s U.S. Manufacturing Footprint

Hengrui Wins NMPA Approval for HRS‑5965 – Complement Factor B Inhibitor for Complement Inhibitor‑Naive PNH Patients
CompanyDrug

Hengrui Wins NMPA Approval for HRS‑5965 – Complement Factor B Inhibitor for Complement Inhibitor‑Naive PNH Patients

CompanyDeals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

CompanyPolicy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

CompanyDrug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

CompanyDeals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Company

Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth

Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%
Company

Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%

CompanyDeals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision